Research programme: MB 5 series - Mito BioPharma
Alternative Names: MB5 series - Mito BioPharmaLatest Information Update: 28 Aug 2022
At a glance
- Originator Mito BioPharma
- Class Antihyperglycaemics; Hepatoprotectants; Small molecules
- Mechanism of Action Mitochondrial oxidative phosphorylation uncouplers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
- 28 Aug 2022 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA
- 10 Jul 2018 Mito BioPharma in-licenses mitochondrial uncouplers technology from Rutgers University before July 2018 (Mito BioPharma website, July 2018)